0093-7485 : Granisetron 1 mg (Granisetron Hydrochloride 1.12 mg) Oral Tablet


NDC0093-7485
Labeler: Teva Pharmaceuticals USA Inc
Product Type: Human Prescription Drug
Drug Name:  Granisetron Hydrochloride
Dosage Form: Oral Tablet, Film Coated
Application #: ANDA078080
Rev. Date: 


Appearance:


Markings: 93;7485
Shapes:  Oval
Colors:  White
Size (mm): 9
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

93 7485: (0093-7485) Granisetron 1 mg (Granisetron Hydrochloride 1.12 mg) Oral Tablet by Teva Pharmaceuticals USA Inc
The above image is provided by the U.S. National Library of Medicine (NLM) and is not part of the official label.

NDC Package Codes:

  • 0093-7485-12: 2 BLISTER PACK IN 1 BOX (0093‑7485‑12) > 1 TABLET, FILM COATED IN 1 BLISTER PACK (0093‑7485‑19)
  • 0093-7485-20: 20 BLISTER PACK IN 1 BOX (0093‑7485‑20) > 1 TABLET, FILM COATED IN 1 BLISTER PACK (0093‑7485‑19)

Active Ingredients:

  • Granisetron Hydrochloride

Dosage Strength:

  • 1 mg

Inactive Ingredients:

  • Hypromelloses
  • Lactose Monohydrate
  • Polyethylene Glycols
  • Magnesium Stearate
  • Cellulose, Microcrystalline
  • Polysorbate 80
  • Sodium Starch Glycolate Type a Potato
  • Titanium Dioxide

Pharmaceutical Classes:

  • Serotonin 3 Receptor Antagonists [MoA]
  • Serotonin-3 Receptor Antagonist [EPC]

Related Products:

Based on records with the same trade name.
  • 0054-0143 Granisetron 1 mg (Granisetron Hydrochloride 1.12 mg) Oral Tablet by Roxane Laboratories, Inc
  • 0143-9744 Granisetron Hydrochloride 1 mg/ml Intravenous Solution by West-ward Pharmaceutical Corp
  • 0143-9745 Granisetron Hydrochloride 4 mg/4ml Intravenous Solution by West-ward Pharmaceutical Corp
  • 16714-221 Granisetron 1 mg (Granisetron Hydrochloride 1.12 mg) Oral Tablet by Northstar Rx LLC
  • 17478-546 Granisetron Hydrochloride 1 mg/ml Intravenous Injection by Akorn Inc.
  • 17478-547 Granisetron Hydrochloride .1 mg/ml Intravenous Injection by Akorn Inc.
  • 25021-778 Granisetron Hydrochloride .1 mg/ml Intravenous Injection by Sagent Pharmaceuticals
  • 25021-779 Granisetron Hydrochloride 1 mg/ml Intravenous Injection by Sagent Pharmaceuticals
  • 25021-781 Granisetron Hydrochloride 1 mg/ml Intravenous Injection by Sagent Pharmaceuticals
  • 42043-390 Granisetron Hydrochloride 1 mg Oral Tablet, Film Coated by Orchidpharma Inc
  • 51079-472 Granisetron 1 mg (Granisetron Hydrochloride 1.12 mg) Oral Tablet by Udl Laboratories, Inc.
  • 51672-4138 Granisetron 1 mg (Granisetron Hydrochloride 1.12 mg) Oral Tablet by Taro Pharmaceuticals U.S.a., Inc.
  • 51991-735 Granisetron 1 mg (Granisetron Hydrochloride 1.12 mg) Oral Tablet by Breckenridge Pharmaceutical, Inc.
  • 55150-175 Granisetron Hydrochloride 1 mg/ml Intravenous Injection, Solution by Auromedics Pharma LLC
  • 55150-176 Granisetron Hydrochloride 4 mg/4ml Intravenous Injection, Solution by Auromedics Pharma LLC
  • 55390-250 Granisetron Hydrochloride .112 mg/ml Intravenous Injection, Solution by Bedford Laboratories
  • 55648-661 Granisetron Hydrochloride 1 mg/ml Intravenous Injection by Wockhardt Limited
  • 55648-662 Granisetron Hydrochloride .1 mg/ml Intravenous Injection by Wockhardt Limited
  • 63126-331 Granisetron Hydrochloride .1 mg/ml Intravenous Injection, Solution by Yung Shin Pharmaceutical Inc. Co., Ltd.
  • 63126-332 Granisetron Hydrochloride 1 mg/ml Intravenous Injection, Solution by Yung Shin Pharmaceutical Inc. Co., Ltd.
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0093-7485 QR Code

< Prev: 0093-7477Next: 0093-7487 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.